You are here

Alysia Lovgren


Lovgren AK, Kovacs JJ, Xie T, et al. Beta-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med. 2011;3:74ra23.

Lovgren AK, Kovarova M, Koller BH. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not PGE2 synthesis. Mol Cell Biol. 2007;27:4416–4430.

Lovgren AK, Jania LA, Hartney JM, et al. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2006;291:L144–L156.

Alysia Lovgren, Ph.D.

Alysia Lovgren is a clinical genomic scientist and analysis team lead in the Medical and Population Genetics Program of the Broad Institute of MIT and Harvard, working under the direction of Anne O’Donnell. Lovgren leads a team of clinical genomic analysts that interprets rare disease exomes and genomes to discover new genes underlying Mendelian diseases and identify causal variants in patients with rare genetic disease. Through the Broad Institute’s Center for Mendelian Genomics, the team works with clinician-scientist collaborators all over the world to accelerate discoveries. The team also analyzes the genomes of undiagnosed rare disease patients through the Rare Genomes Project, a patient-driven research study that partners with families, advocates, and clinicians to improve the rate of rare disease diagnosis and increase patients’ access to genomic research.

Prior to joining the Broad Institute in April 2018, Lovgren was a senior scientist and molecular genetics review analyst at GeneDx. She previously worked as a manuscript editor for American Journal Experts and is a certified triathlon coach and strength and conditioning specialist.

Lovgren holds a Ph.D. in genetics and molecular biology from the University of North Carolina at Chapel Hill. She undertook her postdoctoral research at Duke University. She also holds a B.S. in biology (summa cum laude) from the University of North Florida.

Contact Alysia Lovgren via email at

February 2019